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Introduction
Pompe disease (Glycogen Storage Disease type II, acid
maltase deﬁciency) is an autosomal recessive disorder
caused by deﬁciency of the enzyme acid a-glucosi-
dase. As a result of this deﬁciency, lysosomal glycogen
cannot be degraded and accumulates in the lysosomes
of virtually all body tissues [7, 16]. This leads to a
broad clinical spectrum ranging from a severe, classic
infantile phenotype with generalized muscle weak-
ness, a hypertrophic cardiomyopathy and death
usually before the ﬁrst year of life [28] to a slowly
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j Abstract Objective To investi-
gate the prevalence and severity of
fatigue in adult patients with
Pompe disease. Methods The
Fatigue Severity Scale (FSS) was
assessed in an international pop-
ulation of 225 adults with Pompe
disease, a metabolic disorder pre-
senting as a slowly progressive
proximal myopathy. The FSS
scores were compared to those of
healthy controls and the relation-
ship between the level of fatigue
and other patient characteristics
was investigated. Results The
mean age of the participants was
47 (SD 13) years and the mean
disease duration 11 (SD 8) years.
43% used a wheelchair and 46%
had respiratory support, 29%
needed both. 67% of the partici-
pants had a FSS score ‡5, indi-
cating severe fatigue. The mean
FSS score was 5.2 (SD 1.5), which
was signiﬁcantly higher than that
of healthy controls (p < 0.001).
Fatigue was not related to age, sex
or disease duration. Patients who
used a wheelchair or respiratory
support were on average more
fatigued than those who did not
(p = 0.01). However, of the pa-
tients who did not use these aids,
59% also had a FSS score ‡5. FSS
scores were highest among pa-
tients who reported a high fre-
quency of sleep disorders, but
patients who never experienced
sleep difﬁculties were also fatigued
(mean FSS score = 4.8). Conclu-
sion Fatigue is highly prevalent
among both mildly and severely
affected adult patients with Pompe
disease. The FSS appears a useful
tool in assessing fatigue in Pompe
disease.
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3015 GE Rotterdam, The Netherlandsprogressive proximal myopathy without involvement
of the heart. Patients on this end of the spectrum are
described as having ‘late-onset’ [12, 21] or ‘non-
classic’ [31] Pompe disease and may present at any
age, sometimes as late as the sixth decade of life.
Eventually they may become wheelchair-bound and
dependent on artiﬁcial ventilation [7, 16].
Besides symptoms related to weakness of the
skeletal and respiratory muscles, non-motor problems
such as fatigue can also have a profound and dis-
abling impact on the patients’ lives. Fatigue is difﬁcult
to deﬁne, as it is often a non-speciﬁc and subjective
complaint. Two suggested deﬁnitions are ‘extreme
and persistent tiredness, weakness or exhaustion-
mental, physical or both’ [6] and ‘difﬁculty in initia-
tion of or sustaining voluntary activities’ [3]. Al-
though fatigue is a frequent symptom in many
chronic disorders, it has received little attention in
Pompe disease and was only sporadically reported [4,
20, 23, 27, 32]. In a recent study on the clinical con-
dition of late-onset Pompe patients we found that
76% of the study population reported symptoms of
fatigue and that fatigue was among the ﬁrst com-
plaints for 24% [12]. In the present study, we inves-
tigated the prevalence and severity of fatigue in more
detail in a large, international group of adult patients
with Pompe disease and studied the associations be-
tween fatigue and several other patient characteristics.
Methods
j Patients and procedures
Data were obtained between May 2002 and January 2004 as part of
an ongoing international study on the natural course of Pompe
disease in children and adults [11–13]. The medical ethical com-
mittee of Erasmus MC approved the project and the participants
provided informed consent. Patients were recruited through patient
organisations afﬁliated with the International Pompe Association
(IPA). Participants were asked to complete a booklet of question-
naires, including one on fatigue for the patients of 18 years and
older. The levels of fatigue in our study population were compared
to those of healthy controls that were described previously in a
study on immune-mediated polyneuropathies. This comparison
group consisted of 113 healthy persons, 48% female, with a mean
age of 54 (SD 15) years [22].
j Fatigue assessment
The severity and impact of fatigue was assessed using the Fatigue
Severity Scale (FSS) [19]. The total FSS score is the average of the 9
item scores and ranges from 1 (‘no signs of fatigue’) to 7 (‘most
disabling fatigue’). Scores of 4 and higher indicate that patients are
suffering from fatigue and scores of 5 and higher that patients are
suffering from severe fatigue [9, 15, 22]. We used the validated
English and Dutch translations of the FSS [19, 22], and a German
version that was translated by a certiﬁed translator. The FSS has
demonstrated good internal consistency, reliability and validity in
studies among patients with multiple sclerosis, immune-mediated
polyneuropathies and chronic hepatitis C [18, 19, 22] and is easy to
complete. In the present study, individual item scores were missing
for only 4% of the study population; the maximum number of
missing items per patient was 3. When individual item scores were
missing, the FSS score was calculated with the remaining items.
j Other information
Additional information was gathered on date of birth, year of
diagnosis, sex, use of wheelchair or walking aids, use of respiratory
support, number of hours respiratory support per day, and pres-
ence of sleep disorders as indicated by the patient (‘never’, ‘occa-
sionally’, or ‘often’). Disease duration was calculated as the time
between diagnosis and questionnaire completion.
j Statistical analyses
Differences between countries in age, age at diagnosis, disease
duration and FSS score (UK, USA, The Netherlands and Germany)
were tested using one-way analysis of variance (ANOVA) and in sex,
wheelchair use and use of respiratory support by v
2 tests. Mean
scores of our study population were compared to the scores of
healthy controls by calculating the t ratio using the published mean
and standard deviation [14, 22]. Internal consistency was evaluated
with Cronbach’s alpha coefﬁcient and test–retest reliability with the
intraclass correlation coefﬁcient [24]. The test–retest reliability was
determined in a subgroup of 34 Dutch patients who completed the
FSStwice,withapproximately1monthbetweenbothmeasurements.
The relation between FSS score and age, disease duration and
number of hours ventilation per day was evaluated with Spearman’s
rank correlation coefﬁcient.
Differences in mean FSS score between groups based on
wheelchair and ventilator use and on the self-reported frequency of
sleep disorders were tested with ANOVA. All analyses were per-
formed using SPSS for Windows (version 11.5). A p-value of £0.05
was considered statistically signiﬁcant.
Results
j Patient characteristics
A total of 225 patients of 18 years and older com-
pleted the FSS. The mean age of the study population
was 47 (SD 13) years and 54% were women. The mean
disease duration was 11 (SD 8) years. Forty-three
percent used a wheelchair and 46% used respiratory
support, 29% needed both. The study population in-
cluded patients from the USA (n = 75), the Nether-
lands (n = 50), Germany (n = 50), the UK (n = 17),
Australia (n = 13), Canada (n = 8), Austria (n = 3),
Switzerland (n = 2), Belgium, Denmark, Italy, Lux-
embourg, Spain, New Zealand and Taiwan (all n = 1).
No statistically signiﬁcant differences in patient
characteristics between the countries were found.
j FSS scores
The mean FSS score of the study population was 5.2
(SD 1.5). 78% of the patients had a FSS score of 4 or
higher (‘fatigued’) and 67% a FSS score of 5 or higher
942(‘severely fatigued’). The distributions of item scores
are presented in Table 1. Items on which 75% or more
of the patients scored 5 or higher were mainly related
to physical functioning: ‘my fatigue prevents sus-
tained physical functioning’, ‘fatigue interferes with
my physical functioning’ and ‘exercise brings on my
fatigue’. 65% of the patients classiﬁed fatigue among
their three most disabling symptoms.
The mean FSS score of our study population was
signiﬁcantly higher than the score of healthy controls
(mean FSS score 2.9, p < 0.001). Although the mean
FSS score of the German Pompe patients was lower
than the scores of patients from the UK, USA and the
Netherlands (Fig. 1), it was still signiﬁcantly higher
than that of the Dutch healthy controls (p < 0.001).
The FSS showed excellent internal consistency in our
international study population (Cronbach’s al-
pha = 0.92 for the Dutch version and 0.94 for the
English and German versions) and good 1-month
test–retest reliability in the Dutch subgroup (intra-
class correlation coefﬁcient = 0.86).
j Relationship between fatigue and patient charac-
teristics
FSS scores were not related to sex (p = 0.26), age or
disease duration (r = )0.05 and )0.03, p > 0.47).
Figure 2 shows the FSS score in groups based on
wheelchair and ventilator use. When tested in four
groups, no signiﬁcant differences in FSS score were
found, but patients who did not use a wheelchair or
respiratory support were less fatigued than those who
used one or both of these aids (FSS score = 4.9 vs. 5.4,
p = 0.01). However, even in the group of patients who
did not use a wheelchair or respiratory support, 71%
had a FSS score ‡4 and 59% had a FSS score ‡5.
Within the group of patients who used respiratory
support, FSS scores were not correlated to the number
of hours of ventilation per day (r = 0.06, p = 0.57).
Although the FSS scores differed signiﬁcantly between
patients reporting ‘never’, ‘occasionally’ and ‘often’
sleep disorders, the scores were high in all three
groups (mean FSS score 4.8, 5.3 and 5.6, respectively;
p = 0.01).
Discussion
This study shows that fatigue is prevalent in the entire
spectrum of mildly and severely affected adult pa-
tients with Pompe disease. The FSS scores in this
international group of Pompe patients were signiﬁ-
cantly higher than the scores of healthy controls. Al-
Table 1 Means and distribution of Fatigue Severity Scale item scores of 225
adult patients with Pompe disease
Item Mean
Score
distribution
(%)
1–3 4 5–7
My motivation is lower when I am fatigued 5.7 9 3 88
Exercise brings on my fatigue 5.7 10 6 84
Fatigue interferes with my physical functioning 5.5 14 5 81
My fatigue prevents sustained physical functioning 5.4 18 6 76
I am easily fatigued 5.3 16 9 75
Fatigue interferes with carrying out certain
duties and responsibilities
5.0 23 7 70
Fatigue interferes with my work, family,
or social life
4.9 24 9 67
Fatigue is among my three most
disabling symptoms
4.8 29 6 65
Fatigue causes frequent problems for me 4.8 26 11 63
Item scores range from 1 (strongly disagree) to 7 (strongly agree). The items are
ranked by descending mean item score
Fig. 1 Mean scores (95% CI) on the Fatigue Severity Scale of adult patients
with Pompe disease from different countries. FSS scores differed significantly
between countries when tested with ANOVA (p < 0.001). Scores of healthy
controls were obtained from the literature [22]
Fig. 2 Mean scores (95% CI) on the Fatigue Severity Scale of adult patients
with Pompe disease related to wheelchair use and use of respiratory support
943though we found a signiﬁcant difference in FSS score
between patients with and those without wheelchair
or respiratory support, even in the least affected
group more than half of the patients had FSS scores
‡5, indicating severe fatigue. FSS scores were not
correlated with the duration of disease. The high level
of fatigue in our study population, as measured with
the FSS, is comparable to that of other chronic dis-
orders such as postpoliomyelitis syndrome (mean
score 5.7, mean age 52, SD 8, n = 65) [17] and mul-
tiple sclerosis (mean score 5.3, mean age 45, SD 10,
n = 25) [19].
Although all mean FSS scores were high, signiﬁcant
differences existed between patients from different
countries. The lowest scores were obtained in the
German population. This could not be explained by
differences in general characteristics. It is conceivable
that the impact of fatigue differs somewhat across
countries, since social attitudes, expectations and
roles may differ as well [2]. It should also be noted
that the German translation of the FSS had not been
used before and needs further (cross-cultural) vali-
dation. Yet, excellent internal consistency in all lan-
guages, as well as good reliability, suggests that the
FSS can be a useful tool for assessing fatigue in Pompe
disease.
For an optimal treatment of fatigue it is important
to know why it is so prominently present in Pompe
disease. In a recent review the contribution of ‘central’
and ‘peripheral’ components to fatigue in neurologi-
cal disorders has been discussed [3]. In Pompe dis-
ease, a peripheral cause of fatigue, resulting from
muscle weakness, is perhaps the most likely expla-
nation. Especially relevant with respect to fatigue in
Pompe disease is weakness of the respiratory muscles.
Respiratory insufﬁciency may lead to fragmented
sleep, which in turn may lead to daytime sleepiness
and fatigue [21]. In the present study, patients who
reported ‘often’ or ‘occasionally’ sleep disorders were
on average more fatigued, but patients who reported
to have ‘never’ sleep difﬁculties also had high FSS
scores. It is possible that fragmented sleep due to
respiratory insufﬁciency has remained unnoted in
some of the patients in the latter group, and we and
others previously advised that respiratory function
should be monitored in all patients with Pompe dis-
ease, irrespective of their motor function [12, 25, 29].
Another possible explanation is the relationship
between fatigue and depression [1, 5, 8]. We did not
investigate the presence of depression speciﬁcally, but
found earlier that patients with Pompe disease score
equal to the general population on the mental health
scale of the SF-36, a health-related quality of life
questionnaire [11]. Nevertheless it is recommended to
study the possible inﬂuence of depression in more
detail in future studies, for example by means of the
Hospital Anxiety and Depression Scale [33].
Thus, although a peripheral cause of fatigue is
probably the most important factor, the underlying
mechanisms of fatigue in Pompe disease are in fact not
known yet and a possible central contribution should
not a priori be excluded in future studies. Noteworthy,
in a study with enzyme replacement therapy (ERT) in
three patients with moderate to severe late-onset
Pompe disease, less fatigue and increased energy was
one of the ﬁrst improvements reported by the patients
[30]. This was independent of disease severity and
motor response to treatment. It would therefore be
interesting to include a standardized measure of fati-
gue in future clinical trials on the effect of ERT. In
multiple sclerosis, Guillain-Barre ´ syndrome and
chronic inﬂammatory demyelinating polyneuropathy
adherence to an aerobic training programme resulted
in a signiﬁcant decrease in fatigue and an improve-
ment inphysicalﬁtnessandquality oflife[10,26].Part
of the training effect is probably due to increased ﬁt-
ness of the participants and social aspects of the
intervention [26], and in this respect it is worthwhile
to study the effects of a medically supervised low-
intensity training programme on fatigue and general
well-being of patients with Pompe disease.
In conclusion, our ﬁndings indicate that fatigue is
highly prevalent among adult patients with Pompe
disease. It is present in both mildly and severely af-
fected patients and is independent of disease dura-
tion. The FSS appears a useful tool for the assessment
of fatigue in adult patients with Pompe disease. Fur-
ther research is needed to unravel the pathophysio-
logical mechanism and to identify targets for fatigue
management.
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